Bussiness4 months ago
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results
Metagenomi, Inc. Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September 2024 All Wave 1...
